PMID- 28744284
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20191120
IS  - 1664-3224 (Print)
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 8
DP  - 2017
TI  - Safety and Side Effects of Using Placenta-Derived Decidual Stromal Cells for 
      Graft-versus-Host Disease and Hemorrhagic Cystitis.
PG  - 795
LID - 10.3389/fimmu.2017.00795 [doi]
LID - 795
AB  - Mesenchymal stromal cells (MSCs) are increasingly used in regenerate medicine. 
      Placenta-derived decidual stromal cells (DSCs) are a novel therapy for acute 
      graft-versus-host-disease (GVHD) and hemorrhagic cystitis (HC) after allogeneic 
      hematopoietic stem cell transplantation (HSCT). DSCs are more immunosuppressive 
      than MSCs. We assessed adverse events and safety using DSCs among 44 treated 
      patients and 40 controls. The median dose of infused cells was 1.5 (range 
      0.9-2.9) x 10(6) DSCs/kg. The patients were given 2 (1-5) doses, with a total of 
      82 infusions. Monitoring ended 3 months after the last DSC infusion. Three 
      patients had transient reactions during DSC infusion. Laboratory values, 
      hemorrhages, and transfusions were similar in the two groups. The frequency of 
      leukemic relapse (2/2, DSC/controls) and invasive fungal infections (6/6) were 
      the same in the two groups. Causes of death were those seen in HSCT patients: 
      infections (5/3), respiratory failure (1/1), circulatory failure (3/1), 
      thromboembolism (1/0), multiorgan failure (0/1), and GVHD and others (2/7). 
      One-year survival for the DSC patients with GVHD was 67%, which was significantly 
      better than achieved previously at our center. One-year survival was 90% in the 
      DSC-treated HC group. DSC infusions appear safe. Randomized studies are required 
      to prove efficacy.
FAU - Baygan, Arjang
AU  - Baygan A
AD  - Translational Cell Therapy Research Group (TCR), Division of Therapeutic 
      Immunology, Department of LabMed, Karolinska Institutet, Stockholm, Sweden.
FAU - Aronsson-Kurttila, Wictor
AU  - Aronsson-Kurttila W
AD  - Translational Cell Therapy Research Group (TCR), Division of Therapeutic 
      Immunology, Department of LabMed, Karolinska Institutet, Stockholm, Sweden.
FAU - Moretti, Gianluca
AU  - Moretti G
AD  - Translational Cell Therapy Research Group (TCR), Division of Therapeutic 
      Immunology, Department of LabMed, Karolinska Institutet, Stockholm, Sweden.
FAU - Tibert, Babylonia
AU  - Tibert B
AD  - Translational Cell Therapy Research Group (TCR), Division of Therapeutic 
      Immunology, Department of LabMed, Karolinska Institutet, Stockholm, Sweden.
FAU - Dahllof, Goran
AU  - Dahllof G
AD  - Department of Dental Medicine, Karolinska Institutet, Stockholm, Sweden.
FAU - Klingspor, Lena
AU  - Klingspor L
AD  - Department of Microbiology, Uppsala University Hospital, Uppsala, Sweden.
FAU - Gustafsson, Britt
AU  - Gustafsson B
AD  - Department of Pediatrics, Uppsala University Hospital, Uppsala, Sweden.
FAU - Khoein, Bita
AU  - Khoein B
AD  - Translational Cell Therapy Research Group (TCR), Division of Therapeutic 
      Immunology, Department of LabMed, Karolinska Institutet, Stockholm, Sweden.
FAU - Moll, Guido
AU  - Moll G
AD  - Translational Cell Therapy Research Group (TCR), Division of Therapeutic 
      Immunology, Department of LabMed, Karolinska Institutet, Stockholm, Sweden.
AD  - Charite Universitatsmedizin, Berlin, Germany.
FAU - Hausmann, Charlotta
AU  - Hausmann C
AD  - Center for Allogeneic Stem Cell Transplantation, Department of 
      Pathology/Oncology, Karolinska University Hospital, Stockholm, Sweden.
FAU - Svahn, Britt-Marie
AU  - Svahn BM
AD  - Translational Cell Therapy Research Group (TCR), Division of Therapeutic 
      Immunology, Department of LabMed, Karolinska Institutet, Stockholm, Sweden.
FAU - Westgren, Magnus
AU  - Westgren M
AD  - Department of Obstetrics and Gynecology, Karolinska University Hospital, 
      Stockholm, Sweden.
FAU - Remberger, Mats
AU  - Remberger M
AD  - Center for Allogeneic Stem Cell Transplantation, Department of 
      Pathology/Oncology, Karolinska University Hospital, Stockholm, Sweden.
FAU - Sadeghi, Behnam
AU  - Sadeghi B
AD  - Translational Cell Therapy Research Group (TCR), Division of Therapeutic 
      Immunology, Department of LabMed, Karolinska Institutet, Stockholm, Sweden.
FAU - Ringden, Olle
AU  - Ringden O
AD  - Translational Cell Therapy Research Group (TCR), Division of Therapeutic 
      Immunology, Department of LabMed, Karolinska Institutet, Stockholm, Sweden.
LA  - eng
PT  - Journal Article
DEP - 20170711
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
PMC - PMC5504152
OTO - NOTNLM
OT  - decidual stromal cells
OT  - graft-versus-host disease
OT  - hematopoietic stem cell transplantation
OT  - hemorrhagic cystitis
OT  - mesenchymal stromal cells
EDAT- 2017/07/27 06:00
MHDA- 2017/07/27 06:01
PMCR- 2017/01/01
CRDT- 2017/07/27 06:00
PHST- 2017/02/06 00:00 [received]
PHST- 2017/06/22 00:00 [accepted]
PHST- 2017/07/27 06:00 [entrez]
PHST- 2017/07/27 06:00 [pubmed]
PHST- 2017/07/27 06:01 [medline]
PHST- 2017/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2017.00795 [doi]
PST - epublish
SO  - Front Immunol. 2017 Jul 11;8:795. doi: 10.3389/fimmu.2017.00795. eCollection 
      2017.